Jason M. Broderick

The vaccines did not result in reductions in semen volume, sperm concentration, sperm motility, and total motile sperm count.

Provenge (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant prostate cancer (also referred to as hormone-refractory), has become the first FDA-approved therapeutic vaccine for cancer. The highly anticipated approval follows nearly 2 decades of research and development that included a controversial rejection of the vaccine by the FDA in 2007.